DCGen
Company

Last deal

Amount

Venture - Series Unknown

Stage

01.12.2019

Date

1

all rounds

General

About Company
The company provides a breast cancer prognosis prediction kit.

Industry

Sector :

Subsector :

Keywords :

founded date

2017

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

DCGen is a genomic analysis technology company that offers a cutting-edge multigene assay kit called OncoFREE. This kit predicts prognosis for hormone receptor-positive, HER2-negative early-stage breast cancer patients by analyzing breast cancer tissue RNA expression data. DCGen also offers a test called HOPE that determines the risk for developing hereditary cancer. Their software tools assist with treatment and diagnosis, providing features for decision making, risk analysis, and surgery management.
Contacts